Meeting Overview - The shareholder meeting is scheduled for September 15, 2025, at 14:40 [1] - The meeting will be held at Jiangsu Kangwei Century Biotechnology Co., Ltd., located at 18 Zelan Road, Taizhou, Jiangsu Province [1] - Voting will be conducted through both on-site and online methods using the Shanghai Stock Exchange's network voting system [1] Voting Procedures - The online voting period is from September 15, 2025, during trading hours [1] - Specific voting times for the trading system are from 9:15-9:25, 9:30-11:30, and 13:00-15:00 [1] - Shareholders must complete identity verification to vote online for the first time [3] Agenda Items - The meeting will review several proposals, including: - The completion of certain fundraising investment projects and the permanent allocation of surplus funds to working capital [2] - The cancellation of the supervisory board and amendments to the company's articles of association [2] - The revision of the fund occupation prevention system for controlling shareholders and related parties [2] - The establishment of a remuneration management system for directors and senior management [2] Attendance and Registration - Shareholders registered by the close of trading on September 9, 2025, are eligible to attend [3] - Proxy representation is allowed, with specific documentation required for registration [4] - Registration must be completed by September 12, 2025, at 17:00 [5] Contact Information - The company’s contact address is Jiangsu Kangwei Century Biotechnology Co., Ltd., 4th Floor, Securities Affairs Department, 18 Zelan Road, Taizhou, Jiangsu Province [5] - Contact number: 0523-86200880, Contact person: Wang Tao [5]

证券代码：688426 证券简称：康为世纪 公告编号：2025-030 事会第十四次会议审议，通过了《关于 2024 年限制性股票激励计划第一个归属 期不符合归属条件暨作废已授予尚未归属的限制性股票的议案》，同意对 2024 年限制性股票激励计划中已获授但尚未归属的第二类限制性股票 2,098,400 股全 部取消归属，并作废失效。 江苏康为世纪生物科技股份有限公司 关于 2024 年限制性股票激励计划第一个归属期不符合 归属条件暨作废已授予尚未归属的限制性股票的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏康为世纪生物科技股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开的第二届董事会第十六次会议和第二届监事会第十四次会议审议通过了 《关于 2024 年限制性股票激励计划第一个归属期不符合归属条件暨作废已授予 尚未归属的限制性股票的议案》，同意对 2024 年限制性股票激励计划中已获授但 尚未归属的第二类限制性股票 2,098,400 股全部取消归属，并作废失效。其中 失去了激励资格须予以作 ...

Core Viewpoint - Jiangsu Cowin Biotech Co., Ltd. reported a significant increase in revenue for the first half of 2025, with total revenue reaching approximately 87.12 million yuan, a 29.74% increase compared to the same period last year. However, the company also experienced a net loss of approximately 55.91 million yuan, which is an 11.70% increase in losses compared to the previous year [5]. Company Overview - Jiangsu Cowin Biotech Co., Ltd. specializes in molecular detection technology and has over ten years of research and development experience in core technologies related to molecular detection [6]. - The company has developed over 700 core products, including molecular detection raw enzymes, nucleic acid preservation reagents, nucleic acid extraction and purification reagents, and molecular diagnostic kits [6][9]. - The company holds 74 domestic medical device registration or filing certificates and has obtained overseas medical device registrations for 70 products, establishing a comprehensive product system [6]. Financial Performance - For the first half of 2025, the company reported total revenue of 87,118,671.74 yuan, compared to 67,146,615.25 yuan in the same period last year, marking a 29.74% increase [5]. - The total profit for the period was -60,630,052.93 yuan, slightly worse than the -57,766,203.41 yuan reported in the previous year, indicating a 4.96% increase in losses [5]. - The net profit attributable to shareholders was -55,911,138.36 yuan, compared to -50,056,858.08 yuan in the previous year, reflecting an 11.70% increase in losses [5]. Research and Development - The company has established seven technical platforms and 32 core technologies related to molecular detection, and has been granted 33 domestic invention patents and 61 utility model patents [6]. - The company focuses on the research and development of molecular detection raw enzymes, having developed 186 types of enzymes that are widely applicable in various molecular biology experiments [6][9]. Product Development - The company has launched innovative products in the gastrointestinal and respiratory disease screening and diagnosis fields, including a series of nucleic acid detection kits for Helicobacter pylori, which is a significant risk factor for gastric cancer [9]. - The company has developed nucleic acid preservation reagents that are crucial for molecular detection, with over 70 types of products available, ensuring comprehensive sample collection and preservation capabilities [6][9].

江苏康为世纪生物科技股份有限公司2025 年半年度报告摘要 公司代码：688426 公司简称：康为世纪 规划，投资者应当到 www.sse.com.cn 网站仔细阅读半年度报告全文。 江苏康为世纪生物科技股份有限公司 公司已在本报告"第三节 管理层讨论与分析"之"四、风险因素"中说明了可能对公司产生重大不利 影响的风险因素，敬请投资者注意投资风险。 江苏康为世纪生物科技股份有限公司2025 年半年度报告摘要 第一节 重要提示 整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 无 公司股票简况 | 股票种类 | 股票上市交易所 股票简称 | | 股票代码 | 变更前股票简称 | | | --- | --- | --- | --- | --- | --- | | A股 | 上海证券交易所科创板 康为世纪 | | 688426 | 不适用 | | | 公司存托凭证简况 | | | | | | | □适用 √不适用 | | | | | | | 联系人和联系方式 | | | | | | | 联系人和 | | | | | | | | 董事会秘书（信息披露境内代表） | | 证券事务代表 | | | ...

第五章 回避制度 第一章 总则 第二章 薪酬与考核委员会 董事会对薪酬与考核委员会的建议未采纳或者未完全采纳的, 应当在董事会 决议中记载薪酬与考核委员会的意见及未采纳的具体理由, 并进行披露。 第一条 为保证公司规范经营, 建立有效的监督机制和激励机制, 进一步建立健全公 司董事(非独立董事)及高级管理人员的考核和薪酬管理制度, 完善公司治理结 构, 根据《中华人民共和国公司法》(以下简称"《公司法》")、《上市公司 治理准则》《上市公司独立董事管理办法》等有关法律、法规、规章、规范 性文件和《江苏康为世纪生物科技股份有限公司章程》(以下简称"公司章程") 的规定, 结合公司实际情况, 制定本工作细则。 第二条 董事会薪酬与考核委员会是董事会依据相应法律法规设立的专门工作机构, 主要负责制定公司董事及高级管理人员的考核标准并进行考核; 负责制定、审 查公司董事及高级管理人员的薪酬决定机制、决策流程、支付与止付追索安 排等薪酬政策与方案, 对董事会负责。 第三条 本工作细则所称董事是指在本公司支取薪酬的董事长、董事, 高级管理人员是 指董事会聘任的总经理、副总经理、财务总监和董事会秘书等其他高级管理 人员。 ...

Core Viewpoint - Jiangsu Kangwei Century Biotechnology Co., Ltd. has implemented a "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan to enhance company quality, stabilize the capital market, and support high-quality economic development [2] Group 1: Business Focus and Core Competitiveness - The company focuses on its main business, enhancing customer satisfaction and increasing R&D investment to improve market competitiveness and technological leadership [2] - The company has over ten years of R&D experience in molecular detection core technologies, making it one of the few domestic biotech firms with a complete business layout in this area [2] - The company has expanded its business into the screening and diagnosis of gastrointestinal diseases and respiratory infectious diseases, developing several innovative products and services [2][3] Group 2: Technological Advancements - The company has established a nanopore sequencing platform, which offers advantages such as ultra-long read lengths, compact and flexible equipment, and short sequencing times [3] - The nanopore sequencing technology has significant application potential in research, breeding, and pharmaceuticals [3] Group 3: Financial Performance - The company reported a total profit of -60.63 million yuan, a year-on-year decrease of 4.96%, and a net profit attributable to the parent company of -55.91 million yuan, down 11.70% year-on-year [3] Group 4: Marketing and Sales Strategy - The company has established 11 domestic sales regions and 2 international sales regions, with marketing offices in 12 cities, enhancing product promotion and market coverage [4] - A CRM system has been implemented to strengthen customer relationships and improve customer satisfaction and loyalty [5] Group 5: R&D and Innovation - The company has obtained multiple medical device registrations and patents, with ongoing R&D projects progressing steadily [6] - R&D expenses for the first half of 2025 amounted to 40.81 million yuan, a decrease of 11.32% year-on-year [5] Group 6: Operational Management - The company has improved operational efficiency through refined management practices across sales, R&D, production, and management [10] - Key performance indicators have been established to monitor production, material management, and customer support [12] Group 7: Corporate Governance and Investor Relations - The company emphasizes the importance of corporate governance and internal control systems to protect shareholder rights [13] - A stock incentive plan has been introduced to align the interests of shareholders and employees, involving 182 individuals [14] Group 8: Shareholder Returns - Due to negative net profits, the company does not meet the conditions for profit distribution but plans to use part of the raised funds for share repurchase to enhance investor confidence [15][16]

Core Viewpoint - The announcement details the expected daily related transactions for Jiangsu Kangwei Century Biotechnology Co., Ltd. in 2025, emphasizing that these transactions are necessary for normal business operations and will not adversely affect the company's ongoing viability or independence [1][8]. Group 1: Daily Related Transactions Overview - The board of directors approved the expected daily related transactions for 2025 during meetings held on August 27, 2025, with non-related directors and all supervisors voting in favor [1]. - The transactions are based on normal production and operational needs, adhering to fair and equitable pricing principles [1][7]. Group 2: Expected Amounts and Categories - The expected transaction amounts for 2025 include purchasing raw materials for 15 million yuan and providing labor services for 2 billion yuan [3][4]. - The total expected amount for related transactions is 2.84 billion yuan, with specific categories including vehicle leasing, office space leasing, property management, and technical services [4][6]. Group 3: Related Parties and Relationships - The related parties include Shanghai Tianhao Biotechnology Co., Ltd., which holds a 49% stake in a subsidiary, and Beijing Kangwei, the controlling shareholder of the company [5][6]. - The company maintains a stable cooperative relationship with these related parties, ensuring ongoing transactions [8]. Group 4: Pricing Policies and Agreements - The pricing for related transactions is determined based on market principles, ensuring fairness and non-detriment to the company and its shareholders [7]. - Contracts or agreements will be signed with related parties based on the specific business needs following board approval [7][8]. Group 5: Necessity and Impact of Related Transactions - The expected related transactions are deemed necessary for the company's stable operations and business development, enhancing market competitiveness [7][8]. - The company asserts that these transactions will not lead to dependency on related parties and will not harm the interests of shareholders, particularly minority shareholders [7][8].

一、关于对《关于<2025 年半年度募集资金存放与使用情况的专项报告>的 议案》的独立意见 公司编制的《2025 年半年度募集资金存放与使用情况的专项报告》符合《上 海证券交易所科创板股票上市规则》、 《上海证券交易所科创板上市公司自律监管 指引第 1 号——规范运作》及《上市公司监管指引第 2 号——上市公司募集资金 管理和使用的监管要求》等相关法律法规、规章及《江苏康为世纪生物科技股份 有限公司募集资金管理制度》的规定。不存在改变或变相改变募集资金用途的情 形，不存在损害公司及股东利益的情形，不会对募投项目的实施造成不利影响。 募集资金具体使用情况与公司已披露情况一致，不存在变相改变募集资金用途和 损害股东利益的情况，不存在违规使用募集资金的情况。 综上，我们一致同意通过公司编制的《2025 年半年度募集资金存放与使用 情况的专项报告》。 江苏康为世纪生物科技股份有限公司 独立董事关于第二届董事会第十六次会议 相关事项的独立意见 根据《中华人民共和国公司法》、 二、关于对《关于部分募集资金投资项目结项并将节余募集资金永久补充 流动资金的议案》的独立意见 《中华人民共和国证券法》、 《上海证券交易 所科创板 ...

Core Points - The article outlines the insider information management system of Jiangsu Kangwei Century Biotechnology Co., Ltd, emphasizing the importance of confidentiality and fair disclosure to protect investors' rights [2][3][4]. Group 1: Insider Information Management - The management of insider information is the responsibility of the board of directors, with the board secretary organizing its implementation [2]. - Any department or individual within the company is prohibited from disclosing insider information without board approval [2]. - Insider information is defined as non-public information that could significantly impact the company's operations, finances, or the market price of its securities [2][3]. Group 2: Scope of Insider Information - Insider information includes significant changes in business policies, major investments, important contracts, and any substantial losses or debts [2][3]. - The scope also covers changes in shareholding structures, major lawsuits, and any criminal investigations involving the company or its executives [2][3]. Group 3: Insider Information Recipients - Insider information recipients include company directors, senior management, major shareholders, and individuals who can access insider information due to their roles [3][4]. - The list of insider information recipients must be accurately recorded and maintained for regulatory review [4][5]. Group 4: Confidentiality and Penalties - Individuals with access to insider information are required to maintain confidentiality and are prohibited from trading the company's securities based on that information [6][9]. - Violations of confidentiality or insider trading can lead to penalties, including potential criminal charges [6][9].

江苏康为世纪生物科技股份有限公司 第一章 总则 第一条 为进一步完善江苏康为世纪生物科技股份有限公司(以下简称"公司")法人治 理结构, 明确总经理的职权、职责, 规范总经理的行为, 依据《中华人民共和 国公司法》(以下简称" 《公司法》")和《江苏康为世纪生物科技股份有限公司 章程》(以下简称"公司章程"), 特制定本工作细则。 第八条 总经理应履行下列职责: 第二条 公司设总经理一名。 第三条 总经理对董事会负责, 组织实施董事会决议, 主持公司日常经营管理工作。 第四条 总经理由董事会决定聘任或者解聘。 第五条 总经理每届任期三年, 连聘可以连任。 第二章 总经理的职权 第六条 总经理对董事会负责, 行使下列职权: (一) 主持公司的生产经营管理工作, 组织实施董事会决议, 并向董事会报 告工作; (二) 组织实施公司年度经营计划和投资方案; (三) 拟订公司内部管理机构设置方案; (四) 拟订公司的基本管理制度; (五) 制定公司的具体规章; (六) 提请董事会聘任或者解聘公司副总经理、财务负责人; (七) 决定聘任或者解聘除应由董事会决定聘任或者解聘以外的负责管理人 员; (八) 列席董事会会议; ...